(Reuters) - Drugmakers AstraZeneca, Novartis and Eli Lilly set a cautious tone for 2011, bracing the sector for challenging patent expiries and price pressures from U.S. health reforms. While AstraZeneca cheered investors with above-forecast fourth quarter earnings on Thursday and a surprise promise to buy back $4 billion of shares, it joined its Swiss rival in warning of pressure from generics, U.S. reforms and price cuts.
